Compounded Tirzepatide Recalls Over Sterility: Criminal Exposure for Outsourcing Facilities, Pharmacies and Florida Clinics

Twenty-two vials of compounded tirzepatide are the subject of a nationwide recall, and the small number should not reassure anyone. On October 8, FDA classified the recall of an 18 mg/mL tirzepatide injection and a vial of NAD+ from a North Carolina 503B outsourcing facility because the firm could not assure the products were sterile. Ten months earlier, the same facility received an FDA warning letter describing sterile practices FDA called insanitary.

It is the second compounded tirzepatide sterility recall in a month. A Houston pharmacy recalled tirzepatide-niacinamide vials in late September after an FDA inspection documented microbial growth in its cleanest work area and research-use-only certificates for its active ingredients. For anyone who makes, sells, prescribes or injects compounded GLP-1 drugs in Florida, sterility is the fact that turns a regulatory problem into a criminal one.

Two compounded tirzepatide sterility recalls in a month. Sterility is the fact that turns a regulatory problem into a criminal one.

Key Takeaways

• Fla. Stat. § 499.0051 makes knowingly selling an adulterated drug a second-degree felony, and a first-degree felony if great bodily harm or death results.
• A drug made under insanitary conditions is adulterated under 21 U.S.C. § 351(a)(2)(A), even if no contamination is ever found in the vial.
• Under the Park doctrine, owners and pharmacists in charge can face misdemeanor charges under 21 U.S.C. § 333(a)(1) without proof they knew of the violation.
• Outsourcing facilities shipping sterile compounded drugs into Florida need a nonresident sterile compounding permit under Fla. Stat. § 465.0158 and must meet USP 797.
• Florida clinics and med spas that buy compounded GLP-1 drugs inherit their supplier's risk, and their sourcing records and recall response become evidence.

What the Two Recalls Show

FDA inspected the North Carolina facility in May 2025. Its December 2025 warning letter describes personnel working with exposed skin in the ISO 5 area, the zone where sterile product is open to the air, and an operator blocking first air by holding gloved hands over open sterile containers. FDA cited insanitary conditions and good manufacturing practice failures, named tirzepatide and semaglutide labels, and told the firm its products did not meet the conditions of section 503B and so were not eligible for that section's exemptions. The recall began September 24 and covers 22 lots of tirzepatide with beyond-use dates into late November. FDA has not said whether the recall grows out of the earlier findings, and "lack of assurance of sterility" does not mean contamination was found.

FDA's warning letter describes exposed skin in the ISO 5 area and an operator blocking first air with gloved hands over open sterile containers. Those are the facts a sterility case is built on.

The Houston file is worse on paper. According to Medical Daily, the Form 483 issued after a six-day inspection in August lists 14 observations: aseptic work with exposed hair or skin, weeks of failed pressure readings between clean rooms while lots were released, microbial growth in an ISO 5 hood with no investigation and a lot released anyway, and research-use-only certificates for the tirzepatide and semaglutide ingredients. A Form 483 is not a final FDA finding, and the pharmacy can respond.

No illnesses have been publicly tied to either recall. FDA's broader numbers are less quiet: as of May 31, 2026, the agency had received 990 adverse event reports for compounded semaglutide and more than 730 for compounded tirzepatide, and it says the true numbers are likely higher.

What FDA and Prosecutors Are Building

Start with the legal backdrop. FDA declared the tirzepatide shortage over in late 2024, and the grace periods for compounders ended in early 2025. A 503A pharmacy may not regularly compound essentially copies of a commercially available drug under 21 U.S.C. § 353a, and an outsourcing facility may use a bulk ingredient under § 353b only if it is on the clinical need list or the drug is in shortage. Tirzepatide is neither, and on May 1, 2026, FDA proposed keeping it off the 503B bulks list permanently, along with semaglutide and liraglutide. The government starts from the view that much GLP-1 compounding should not exist.

Sterility turns that view into a public safety case. Inspection, Form 483, warning letter and recall form a paper trail, and each document proves the firm was on notice. A compounder that keeps shipping after notice hands prosecutors the intent element. That is the file an FDA OCI investigation is built to finish.

The Criminal Precedents Are Real

After a 2011 outbreak of bloodstream infections tied to contaminated intravenous nutrition in which nine infected patients died, an Alabama pharmacy's pharmacist in charge and its president pleaded guilty to FDCA misdemeanors and received 12 and 10 months in prison.

In the 2012 fungal meningitis outbreak, a Massachusetts compounding center's owner shipped injections before sterility results came back and never told customers about failed tests. He was convicted of racketeering, mail fraud and introducing misbranded drugs with intent to defraud, and after United States v. Cadden, 965 F.3d 1 (1st Cir. 2020), he was resentenced to 174 months. Michigan then brought its own case, and in 2024 he pleaded no contest to 11 counts of involuntary manslaughter.

Inspection, Form 483, warning letter and recall form a paper trail. A compounder that keeps shipping after notice hands prosecutors the intent element.

The Charges: Florida Law First, Then Federal

Florida does not need FDA to act. A drug prepared under conditions where it could have been contaminated with filth is adulterated under Fla. Stat. § 499.006(2). Knowingly selling, delivering or holding an adulterated drug for sale is a second-degree felony under § 499.0051(13), punishable by up to 15 years. Because § 499.003(11) defines every adulterated drug as a contraband prescription drug, the act's top tiers apply too: a first-degree felony at $25,000 in value, a first-degree felony if great bodily harm results, and up to life if a death results.

Florida also controls who may ship sterile compounded product into the state. Under § 465.0158, a nonresident pharmacy or outsourcing facility needs a nonresident sterile compounding permit, written policies that comply with USP 797, and a current inspection report, and it may not ship product that fails Florida's sterile compounding standards. A Florida clinic buying from a supplier without that permit has a sourcing problem before any recall.

Federally, section 503B exempts outsourcing facilities from the new drug approval, labeling and track-and-trace provisions. It does not exempt them from adulteration. A drug is adulterated under § 351(a)(2)(A) if made under insanitary conditions, and under § 351(a)(2)(B) if made outside current good manufacturing practice. Shipping it violates 21 U.S.C. § 331(a), and holding it under insanitary conditions after interstate shipment can violate § 331(k).

The penalties run in three tiers. Under § 333(a)(1), a violation is a misdemeanor without proof of intent, and under United States v. Park, 421 U.S. 658 (1975), an owner or pharmacist in charge with authority to prevent the violation can be convicted without knowing about it. With intent to defraud or mislead, § 333(a)(2) makes it a three-year felony. And § 333(b)(7) carries up to 20 years for knowingly and intentionally adulterating a drug with a reasonable probability of causing serious harm or death. Releasing a lot after finding microbial growth in the hood is the kind of fact prosecutors would test against that statute.

Fraud counts come next. Telling customers a product was sterile, tested or made under good manufacturing practice when it was not supports mail and wire fraud under 18 U.S.C. § 1341 and § 1343, the theory behind the Massachusetts case. Where an insurer paid, healthcare fraud under 18 U.S.C. § 1347 follows. Compounding from a research-use-only ingredient breaks the § 353a requirement of a compliant ingredient from a registered manufacturer with a valid certificate of analysis, which converts the product into an unapproved new drug as well.

Mistakes Clinics and Compounders Make After a Recall

• Treating the recall letter as paperwork. Quarantine the lot, stop administering it and identify every patient who received it. A clinic that keeps injecting after notice is holding an adulterated drug for sale, and knowledge is no longer in doubt.
• Fixing the records. Rewriting batch records, cleaning logs or environmental monitoring data after the fact can be charged as obstruction under 18 U.S.C. § 1519, a 20-year felony. The original record, warts and all, is easier to defend.
• Talking freely during the inspection. You must allow an inspection under 21 U.S.C. § 374. You do not have to give investigators an unscripted interview, and what staff say often ends up in the inspection report.
• Answering the 483 or warning letter alone. FDA expects a response within 15 working days, and it is the first written statement in what may become a criminal case.
• Buying on price. A supplier with no Florida permit, no FDA registration or ingredients sold for research use is a supplier whose problems become yours.

Consider a Boca Raton weight-loss clinic that switches to an out-of-state outsourcing facility charging half what its last supplier did. The recall notice arrives by email and sits unread for two weeks while staff keep injecting from the same lot. One patient develops an abscess at the injection site. The clinic now faces a state question about holding an adulterated drug for sale, a federal question about distribution after notice, and a records gap it cannot close after the fact.

"Rewriting batch records, cleaning logs or environmental monitoring data after the fact can be charged as obstruction. The original record, warts and all, is easier to defend."— Aaron M. Cohen, Principal Attorney

How We Defend These Cases

Federal investigation defense in a compounding case starts with posture. An inspection, a Form 483, a warning letter, a recall, a call from an FDA OCI agent and a federal grand jury subpoena each mean something different, and the response has to match where the government is.

We then build our own record through counsel, so it stays privileged: batch records, environmental monitoring, sterility and endotoxin results, ingredient sourcing and certificates of analysis, reviewed with an independent sterile compounding expert. A response to a 483 or warning letter should commit to remediation without conceding the facts that prove intent.

Individuals need their own counsel. Under Park, the owner, the pharmacist in charge and the quality lead each have personal exposure, and their interests can diverge from the company's quickly. For clinics and med spas, the work is documenting supplier diligence and the recall response before anyone asks for it. If a case does move forward, a white collar defense attorney who knows the difference between a Park misdemeanor and a fraud felony knows where that line sits and argues for the right side of it from the first contact.

Why Timing Matters Now

Two sterility recalls in a month, a pending proposal to close the 503B door on tirzepatide, and rising adverse event counts are the conditions in which FDA refers cases to prosecutors, and for Florida clinics those referrals land in the Southern District of Florida and the Middle District of Florida. The general federal limitations period is five years under 18 U.S.C. § 3282, so compounding since the shortage ended remains chargeable. If you are under federal investigation, you may not know it until a target letter arrives. The window to shape the outcome is the period before that letter, while the record is still being written.

Common Questions

Facing a Compounding or Sterility Investigation in Florida?

If you own or work in a compounding pharmacy, outsourcing facility, med spa or telehealth practice and you have received a Form 483, a warning letter, a recall notice, a federal grand jury subpoena or a call from an agent, get advice before you respond. AMC Defense Law represents pharmacies, pharmacists, clinic owners and prescribers in FDA and DOJ investigations involving compounded and unapproved drugs, from our Boca Raton office and nationwide.

AMC Defense Law represents pharmacies, pharmacists, clinic owners and prescribers in FDA and DOJ investigations involving compounded and unapproved drugs, from Boca Raton and nationwide.

Consultations are confidential. Call 561-542-5494 or email amc@amcdefenselaw.com. If you or your loved ones have been arrested or are under investigation, call Aaron M. Cohen, 24 hours a day to get help.

This article is general information, not legal advice, and reading it does not create an attorney-client relationship. Facts are drawn from published reporting and public government records linked above. A Form 483 lists inspectional observations and is not a final agency determination, recalls are not findings of contamination, and every person is presumed innocent unless and until proven guilty. Prior results do not guarantee a similar outcome.